Pliant Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Pliant Therapeutics's estimated annual revenue is currently $10M per year.
- Pliant Therapeutics received $62.0M in venture funding in July 2018.
- Pliant Therapeutics's estimated revenue per employee is $85,812
- Pliant Therapeutics's total funding is $207.4M.
- Pliant Therapeutics's current valuation is $457M. (January 2022)
Employee Data
- Pliant Therapeutics has 117 Employees.
- Pliant Therapeutics grew their employee count by 18% last year.
Pliant Therapeutics Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $54.7M | 272 | 35% | N/A | N/A |
#2 | $1.2M | 6 | N/A | N/A | N/A |
#3 | $26.3M | 131 | 3% | N/A | N/A |
#4 | $35M | 124 | 0% | $62.5M | N/A |
#5 | $21.9M | 109 | 10% | N/A | N/A |
#6 | $137.5M | 684 | -4% | N/A | N/A |
#7 | $14.9M | 86 | 16% | $173M | N/A |
#8 | $91.3M | 454 | N/A | N/A | N/A |
#9 | $64.5M | 321 | -7% | N/A | N/A |
#10 | $9.4M | 47 | 0% | N/A | N/A |
What Is Pliant Therapeutics?
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF- modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant's co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
keywords:N/A
$207.4M
Total Funding
117
Number of Employees
$10M
Revenue (est)
18%
Employee Growth %
$457M
Valuation
N/A
Accelerator
Pliant Therapeutics News
As at December 2021, Pliant Therapeutics had cash of US$201m and no debt. In the last year, its cash burn was US$77m. So it had a cash runway of...
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of Buy by Analysts. Posted by admin on Apr 17th, 2022.
Pliant Therapeutics Inc · Roche Holdings AG's · PLRX believes PLN-74809 can improve upon existing therapies across efficacy and safety/...
He currently serves on the board of directors of Pliant Therapeutics. Dr. Curnutte holds an A.B. in Biochemistry and Molecular Biology from ...
SOUTH SAN FRANCISCO, June 27, 2019 /PRNewswire/ -- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4M | 120 | 10% | $308.6M |
#2 | $199.8M | 124 | 49% | $333.1M |
#3 | $19.7M | 127 | 34% | $159.9M |
#4 | $20M | 129 | 95% | $195.7M |
#5 | $47.7M | 135 | 11% | N/A |
Pliant Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-02-19 | $45.0M | A | Third Rock Ventures, LLC | Article |
| 2018-07-17 | $62.0M | B | Cowen Healthcare Investments | Article |
